Pressure Mounts on BAT to Move Primary Listing to US

Mar.22.2023
Pressure Mounts on BAT to Move Primary Listing to US
British American Tobacco may quit London stock market for US due to growing US focus.

According to reports, British American Tobacco (BAT) is facing pressure from at least one major shareholder to abandon its listing on the UK stock exchange and make the US its primary listing location. Losing BAT would be a significant blow to the capital markets, causing the FTSE 100 Index to lose a key player worth $80 billion.


The reasons for agreeing are simple. London-based British American Tobacco is increasingly centering itself around the United States. From 2017 to present, revenue from its largest single market has risen from 21.3% to 45.7%. The company's European and North African markets, including the UK, make up 22.9%, down from 31.2% five years ago. At this stage, a more appropriate name might be American British Tobacco. Due to being overlooked by domestic investors, British American Tobacco's trading volume has declined, creating a discrepancy in valuation compared to PMI, which is listed on the New York Stock Exchange.


Last year, British American Tobacco (BAT), the company behind the Pall Mall and Lucky Strike brands, generated higher revenue and operating profits than Philip Morris International (PMI), but its stock value lags far behind PMI. As of last Friday's close, PMI had a market capitalization of $149 billion, up over 80% from the previous year. Moving its main listing to New York will bring BAT closer to its largest shareholder, make it easier to access larger liquidity pools, and potentially help narrow the valuation gap. According to Rajiv Jain, the Chairman of BAT shareholder GQG, staying on the UK stock market no longer makes sense for tobacco manufacturers.


It is worth doubting whether the valuation gap is truly related to the listing location of BAT. PMI is listed in the United States, but its operations are overseas. The company was separated from its former parent company Altria Group Inc. in 2008, with Altria retaining its US operations. BAT's price-to-earnings ratio remains consistent with that of Altria. This makes sense because both companies are US-based enterprises.


In fact, the relationship between fundamental factors of a business and valuation differences may be more significant than geographical location. Altria suffered losses due to its $12.8 billion investment in Juul, an e-cigarette manufacturer accused of targeting underage users, five years ago. This year, Altria divested its stake in Juul and obtained Juul's heated non-burning patent technology in return.


Meanwhile, Philip Morris International (PMI) has been developing reduced-harm alternatives to traditional cigarettes at a faster pace, which is what large tobacco companies are relying on for their future success. The company is a leader in the tobacco industry and has achieved significant success in Japan through its IQOS heat-not-burn product. Last year, PMI acquired Swedish Match, a manufacturer of nicotine pouches, for approximately $16 billion, adding another non-combustible tobacco business to its portfolio. Furthermore, through distribution in the US, PMI has been able to re-establish itself in the largest tobacco alternatives market, 14 years after it was split from Altria. It also reached an agreement with Altria Group to sell IQOS in the US last year.


Last year, smoke-free revenue accounted for one-third of PMI's total revenue, with the company aiming to increase this to over 50% by 2025. Meanwhile, BAT's smoke-free revenue proportion for 2022 is just 15%, although the company has been catching up by launching products such as Vuse e-cigarettes, glo "heat-not-burn" products, and Velo nicotine pouches. However, BAT also faces other challenges, such as the proposed ban on menthol cigarettes by the US Food and Drug Administration (FDA). Bloomberg analyst Duncan Fox estimates that these products account for about 35% of BAT's revenue in the US and 16%-17% of total sales. As PMI does not sell cigarettes in the US, it is not at risk from this potential regulation, but it is putting pressure on BAT's stock price.


Delaying the initial public offering (IPO) of BAT comes with costs and risks. It would mean that BAT would lose its position as a constituent of the FTSE 100 index, and there is no guarantee that it will be included in equivalent benchmark indices in the US. If BAT withdraws from London, some UK funds that hold domestic business authorizations may have to divest. The impact on relative investment flows and tax treatment must be considered. Listing in the US requires the approval of 75% of BAT shareholders, making it unlikely without strong support from GQG. American investors can already purchase BAT shares through American depositary receipts (the company is also undergoing a secondary listing in Johannesburg).


Preparing for a world without smoking takes time and investment, and regulatory challenges are never far away. For investors, seeking a quick fix to boost BAT stocks may be tempting, and New York may not provide it.


Reference:


Leaving London may not significantly improve the financial performance of BAT's stock.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
During its coverage of Altria's booth at NACS Show 2026, 2Firsts documented product displays that prompted questions about U.S. tobacco advertising warning requirements. Following public comments from a former FDA official, 2Firsts sought responses from Altria and independently consulted U.S. regulatory lawyer Azim Chowdhury. Altria maintained that its B2B communications complied with applicable laws, while Chowdhury explained that federal warning rules provide no general trade-show exemption for e-cigarettes and nicotine pouches. The special report examines the broader regulatory implications.
Nov.04
Product | Japan Tobacco Expands Nordic Spirit Nicotine Pouch Range to Eight SKUs in Japan, Launches Melon Variant and Broadens Mint Retail Distribution
Product | Japan Tobacco Expands Nordic Spirit Nicotine Pouch Range to Eight SKUs in Japan, Launches Melon Variant and Broadens Mint Retail Distribution
Japan Tobacco Inc. (JT) launched Nordic Spirit Rich Melon Medium through selected tobacco retailers in Japan on November 2, 2026, while expanding physical retail distribution for three existing mint products previously sold through the CLUB JT online store. The melon launch brings Nordic Spirit's Japanese portfolio to eight SKUs. All four products are manufactured in Sweden, contain a standard 14 pouches per can and retail for ¥500 including tax. Since introducing Nordic Spirit in Japan in March, JT has expanded the brand's product lineup and distribution through its online store, convenience stores and selected tobacco retailers.
product
Nov.04
Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Philip Morris Japan (PMJ) launched the limited-edition IQOS ILUMA i PRIME Soundsorial Model in collaboration with French audio brand DEVIALET on October 1, 2026. Featuring sound-wave patterns, a silver-and-black finish and a gradient holder, the heated tobacco device is priced at JPY 15,980, including tax, and is available at four IQOS stores in Japan. According to Japanese media citing a PMJ representative, about 1,900 units were allocated to the Japanese retail market. A separate Soundsorial Collection, combining the device with DEVIALET Gemini II earbuds, includes 440 sets allocated to Japan for a membership prize draw.
product
Oct.23
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
U.S. nicotine pouch startup Skoka Inc. has raised $21.5 million and committed $15 million to an FDA regulatory and scientific research program. Founder Dan Aziz previously built dietary supplement brand Premama, which was acquired by Dr. Reddy's Laboratories in 2023. Skoka is combining proprietary formulations, ingredient transparency and equity investment from professional athletes. The company submitted a bundled PMTA covering 55 products on October 1, 2026. Aziz said Skoka declined an opportunity to enter retail in 2025, prioritizing product research and regulatory submissions instead. It now targets a U.S. retail launch in 2027, subject to FDA requirements. Its products have not received marketing authorization.
Business
Nov.04
North Carolina Tightens Vape Product Directory Enforcement, Expands State and Local Powers as Violators Face Fines, Product Seizures and License Suspension or Revocation
North Carolina Tightens Vape Product Directory Enforcement, Expands State and Local Powers as Violators Face Fines, Product Seizures and License Suspension or Revocation
North Carolina has expanded enforcement of its vapor product directory rules, authorizing more state and local law enforcement participation and establishing a task force led by the State Bureau of Investigation. The legislation requires at least one unannounced compliance inspection annually for retailers, distributors and wholesalers handling covered products. Penalties effective October 1, 2026, include civil fines of $500–$750 for a first violation and $1,000–$1,500 for repeated violations within 12 months, along with potential license suspension or revocation. Manufacturers may face penalties of $10,000 per unlisted product. The measures strengthen the product directory system established in 2024.
Regulations
Oct.28
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
Germany collected €9.789 billion in total tobacco tax revenue from January through August 2026, down 10.8% from a year earlier, according to the Federal Ministry of Finance. Germany's tobacco tax base covers not only cigarettes and fine-cut tobacco but also heated tobacco and vaping liquids taxed as tobacco substitutes. The German Association of the Tobacco Industry and Novel Products, or BVTE, citing federal statistical data, said tax-paid cigarette volume fell 12.6% to 40.6 billion sticks. BVTE is using the latest figures to argue against further tax increases planned from 2027 through 2030, while Germany's parliament is scheduled to hold a first reading of the bill on September 24.
Sep.23